Company intelligence / Profile preview

Eye Therapies

London, United Kingdomeyespecialistsnova.com ↗

Ownership: Private
Development stage: Commercial

Overview

EyeBiotech has developed a pipeline of novel therapies for retinal diseases. Its lead asset, Restoret, is a tri-specific agonist monoclonal antibody targeting the Wnt signaling pathway to address unmet needs in back-of-the-eye diseases such as wet AMD and DME. The company has raised significant venture funding and was acquired by Merck to accelerate its clinical development[5][6].

Therapeutic areas: Ophthalmology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Partnerships

SV Health InvestorsSamsara BioCapitalJeito CapitalMRL Ventures Fund (Merck corporate venture arm)[1][3]

Beyond the preview

Go deeper on Eye Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eye Therapies.

Explore the full profile